| Budget Amount *help |
¥2,300,000 (Direct Cost: ¥2,300,000)
Fiscal Year 2020: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2019: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2018: ¥900,000 (Direct Cost: ¥900,000)
|
|---|
| Outline of Annual Research Achievements |
In this study, we have confirmed that Sipa1-deficient (Sipa1-/-) mice showed increased resistance to different epithelial cancer cells such as MC38 intestinal and IPmN pancreatic cancers in addition to chronic myelogenous leukemia (CML) stem cells. We performed single cell RNA sequencing (scRNA-seq) analysis of tumor stromal cells to investigate the involvement of the tissue stromal response in the anti-tumor mechanism. The analysis results revealed that tumor tissue mesenchymal stromal cells (MSCs) consisted of 3 major subtypes, FA, FB, and FC, with distinct gene expression profiles. We identified these 3 different tumor MSC subtypes quantitatively by FACS analysis using specific cell surface markers. With the analysis, we found that MSCs in the tumor tissue of Sipa1-/- hosts showed preferential increase in FC and FB subtypes, which have both immunoregulatory and extracellular matrix (ECM)-regulatory functions, respectively, as compared to those of wild type (WT) hosts. Furthermore, we also found that the tumor MSCs of Sipa1-/- hosts exhibited enhanced expression of T-cell chemokine gene compared to those of WT hosts. In order to verify their topological relation to tumor cells and infiltrated T cells in WT and Sipa1-/- hosts, tissue immuno-staining analysis was also performed to identify the three MSCs subtypes in situ in various tumor tissues.
All of our results have suggested that host Sipa1-deficiency causes altered pattern of MSC development and their gene expression profile in tumor tissues, leading to the enhanced local T-cell immunity against tumor cells.
|
